Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studiesMaria Carmela Piccirillo, Cesare Gridelli, Luigi Cavanna et al.|Annals of Oncology|2017Cited by 1
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patientsMaria Lucia Iacovino, Francesco Perrone, Laura Arenare et al.|Lung Cancer|2026Cited by 0